Meeting Agenda
For this hearing, the Senate Committee on Finance will follow guidelines developed in consultation with the Office of the Attending Physician (OAP), the Senate Sergeant at Arms, and the Senate Rules Committee to protect the health of Members, witnesses, staff and the public. This includes maintaining six-foot social distance spacing in the hearing room.
Pursuant to guidance from the CDC and OAP, Senate office buildings are not open to the public other than official business visitors and credentialed press at this time. Accordingly, in-person visitors cannot be accommodated at this hearing. We encourage the public to utilize the Committee’s livestream of the hearing, available on the website at http://www.finance.senate.gov.
All hearings are webcast live and will not be available until the hearing starts. Individuals with disabilities who require an auxiliary aid or service, including closed captioning service for webcast hearings, should contact the committee clerk at 202-224-4515 at least three business days in advance of the hearing date.
Questions about the feed or general questions about media attendance can be directed to: Michael_Zona@finance.senate.gov
Member Statements
-
Chuck Grassley
R - IA -
Ron Wyden
D - OR
PANEL ONE
-
Judith A. McMeekin, Pharm.D.
Associate Commissioner for Regulatory Affairs, Office of Regulatory AffairsFood and Drug AdministrationSilver Spring, MD -
Douglas Throckmorton M.D.
Deputy Director for Regulatory Programs, Center for Drug Evaluation and ResearchFood and Drug AdministrationSilver Spring, MD -
Mark Abdoo
Associate Commissioner for Global Policy and StrategyFood and Drug AdministrationSilver Spring, MD -
Mary Denigan-Macauley, Ph.D.
Director, Health CareUnited States Government Accountability OfficeWashington, DC
PANEL TWO
-
Martin VanTrieste
President & Chief Executive Officer,CivicaRxLehi, UT -
David Light
Founder and CEOValisureNew Haven, CT
Related Files
-
Q1a Data for China
-
Q1b Data for China
-
Q1a Data for India
-
Q1b Data for India
-
Q2 Product List (Part 1)
-
Q2 Product List (Part 2)
-
Q2 Product List (Part 3)
-
Q2 Product List (Part 4)
-
GFI Production
-
COVID-19 and Beyond: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process